CIMT Cancer Cell Therapy Summit
Meeting Description
This meeting collaboration between the Association for Cancer Immunotherapy CIMT and the Champalimaud Foundation addressed promising paths towards effective cellular treatment modalities for patients with solid cancer and discuss the boundaries of synthetically engineered immune cells. The meeting covered the innovation gap between academic and small biotech driven research, and the challenges of safe, biologically, and clinically relevant phase I / II clinical trials.
The summit sessions offered a patient-focused perspective on cell therapy possibilities by addressing the quality and nature of the “cellular product” as the starting material for cell therapy; patient-specific therapy and product development including molecular engineering; longevity and “fitness” of cell products after adoptive transfer, and mobilization of autologous anti-cancer directed T-cell responses.
Speakers and meeting program
Speakers included:: Sebastian Klobuch (Netherlands Cancer Institute), Davide Bedognetti (Kite Pharma), Sebastian Kobold (University Medical Center of Munich), Mirjam Heemskerk (Leiden University Medical Center), Stanley Qi (Stanford University), Tal Danino (Columbia University), Andreas Mackensen (University Hospital Erlangen), Judith Kroep (Leiden University Medical Center), Christian Blank (Netherlands Cancer Institute), Jason Bock (CTMC/MD Anderson Cancer Center), Marie Henriksson (Karolinska Institutet), Cécile Alanio (Curie Institute), Boro Dropulic (Caring Cross)
Program schedule Overview 📄
Program Brochure
Location and venue 📄
The CIMT Cell Therapy Summit took place at the Champalimaud Foundation in Lisbon.
Address: Avenida Brasília, 1400-038 Lisbon - Portugal
Scientific Program Committee
Franco Marincola, Christoph Huber, Kees Melief, Dolores Schendel, Özlem Türeci, Alexander Eggermont, Markus Maeurer